Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis

Phase 1TerminatedNCT03310320

AstraZeneca9 enrolled

Overview

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated. The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.

This is a randomised, double-blind, placebo-controlled, multi-centre, parallel group Phase 1b study, designed to evaluate the pharmacodynamic effects, clinical efficacy and safety of AZD0284 compared with placebo as measured by the relative change from baseline in Psoriasis Area Severity Index (PASI score), other disease assessments of involved body surface area (BSA), static physicians global assessment score (sPGA), pruritis and biomarkers associated with the mechanism of disease and AZD0284. Disease activity will be assessed throughout the study as will changes in skin biopsy biomarkers. The study population will be comprised of patients with moderate to severe plaque psoriasis as defined by PASI score, BSA and sPGA. Following completion of screening assessments and meeting all eligibility criteria, patients will be randomised to receive AZD0284 or placebo for 4 weeks of treatment followed by a 4 week follow up period

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Plaque Psoriasis Vulgaris

Interventions

AZD0284 oral solution 2.5 mg/mLDRUG

AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks

PlaceboDRUG

Placebo for AZD0284 oral solution, twice daily for 4 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of signed informed consent prior to any study specific procedures. * At least 6 months documented history with a diagnosis of moderate to severe plaque psoriasis as defined by the Psoriasis Area and Severity Index (PASI), psoriasis Body Surface Area (BSA) and static Physician Global Assessment (sPGA). Exclusion Criteria: * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study. * History and/or presence of tuberculosis, hepatitis, HIV. Other opportunistic infections within 6 months of the study. * Clinically significant laboratory abnormalities. * Clinically important abnormalities in rhythm, conduction or morphology of the digital Electrocardiogram (ECG) as considered by the Investigator may interfere with the interpretation of study data. * Current treatment or treatment for psoriasis with biological therapies within 6 months of study. * Efficacy and safety failure of biologic therapies targeting the IL-17 and IL12/23 pathway at any time. * Current treatment or history of treatment for psoriasis with non-biological systemic medications within 4 weeks of Day 1

Locations (4)

Research Site

Aarhus C, Denmark

Research Site

Copenhagen, Denmark

Research Site

Hellerup, Denmark

Research Site

Odense, Denmark

Outcomes

Primary Outcomes

Reduction from baseline to the end of treatment, in gene expression level of IL-17A and CCL20 relative to placebo.

Time frame: 4 weeks

Percent improvement from baseline to the end of treatment in individual Psoriasis Area and Severity Index (PASI) compared to placebo

Change (percent improvement) in Psoriasis Area and Severity Index score(PASI) compared to placebo

Time frame: 4 weeks

Secondary Outcomes

Proportion of patients achieving 75 % reduction from baseline in PASI score, i.e. PASI 75, at week 4

Percent patients acheiving a 75% reduction in PASI score

Time frame: 4 weeks

Proportion of patients achieving 50 % reduction from baseline in PASI score, i.e. PASI 50, at week 4

Percent patients acheiving a 50% reduction in PASI score

Time frame: 4 weeks

Reduction in static physician's global assessment (sPGA) score from baseline at week4

The change in the Static physician's global assessment (sPGA) score will be assessed

Time frame: 4 weeks

Percent improvement from baseline in involved body surface area (BSA) at week 4

The percent change in the involved body surface area (BSA) will be assessed

Time frame: 4 weeks

Reduction in the pruritus visual analogue scale (pVAS) score from baseline, at week 4

The reduction in the pruritus visual analogue scale (pVAS) score as determined by the patient will be assessed

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.